Katharine Knobil serves as Chief Medical Officer and Head of Research and Development of the Company. Prior to joining us, Dr. Knobil served in various roles at GlaxoSmithKline plc, a pharmaceutical company, from January 1997 until December 2018, including Chief Medical Officer, Senior Vice President of Value Evidence and Outcomes, Vice President of Medicines Development, Global Vice President of Respiratory Clinical Development at the Respiratory and Immunoinflammation Medicines Development Centre and Global Vice President of COPD and NCEs at the Respiratory Medicines Development Centre. Dr. Knobil was on the board of directors of the National Health Council from January 2017 to December 2018 and was a member of the National Academies of Sciences Engineering and Medicine’s Drug Forum. She received a B.A. in biology from Cornell University and an M.D. from The University of Texas Southwestern Medical School.
As the Chief Medical Officer and Head of Research and Development of Kaleido Biosciences Inc, the total compensation of Katharine Knobil at Kaleido Biosciences Inc is 1,251,760$. There are 1 executives at Kaleido Biosciences Inc getting paid more, with Jerald Korn having the highest compensation of 1,505,420$.
Katharine Knobil is 56, she's been the Chief Medical Officer and Head of Research and Development of Kaleido Biosciences Inc since 2018. There are 8 older and 9 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.
Katharine's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over 0$ worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth 32,952,342$ . The most active insiders traders include Ventures Fund Iv General Pa...、Joshua T Brumm、Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of 55$. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth 230,000$.
the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.
Kaleido Biosciences Inc executives and other stock owners filed with the SEC include: